Key Points
- China has ditched mandatory quarantines for arrivals and allowed travel to resume across its border with Hong Kong.
- The move came soon after Japan toughened COVID-19 rules for travellers coming directly from China.
- With the virus let loose, China has stopped publishing daily infection tallies.
China has suspended issuing short-term visas in South Korea and Japan after announcing it would retaliate against countries that required negative COVID-19 tests from Chinese travellers.
China has ditched mandatory quarantines for arrivals and allowed travel to resume across its border with Hong Kong since Sunday, removing the last major restrictions under the "zero-COVID" regime which it abruptly began dismantling in early December after historic protests against the curbs.
But the virus is spreading unchecked among its 1.4 billion people and worries over the scale and impact of its outbreak have prompted Japan, South Korea, the United States and other countries to require negative COVID-19 tests from travellers from China.
Although China imposes similar testing requirements for all arrivals, foreign ministry spokesman Wang Wenbin told reporters on Tuesday entry curbs for Chinese travellers were "discriminatory" and China would take "reciprocal measures".
In the first retaliatory move, the Chinese embassy in South Korea suspended issuing short-term visas for South Korean visitors.
It would adjust the policy subject to the lifting of South Korea's "discriminatory entry restrictions" against China, the embassy said on its official WeChat account.
The Chinese embassy in Japan later announced a similar move, saying that the mission and its consulates had suspended the issuing of visas from Tuesday.
The embassy statement did not say when they would resume.
The move came soon after Japan toughened COVID-19 rules for travellers coming directly from China, prescribing a negative result of a PCR test taken less than 72 hours before departure as well as a negative test on arrival in Japan.
With the virus let loose, China has stopped publishing daily infection tallies.
It has been reporting five or fewer deaths a day since the policy U-turn, figures that have been disputed by the World Health Organisation and are inconsistent with funeral providers reporting surging demand.
Some governments have raised concerns about China's data transparency as international experts predict at least one million deaths in the country this year.
China dismisses criticism over its data as politically-motivated attempts to smear its "success" in handling the pandemic and said any future mutations are likely to be more infectious but less harmful.
"Since the outbreak, China has had an open and transparent attitude," the foreign ministry's Wang said.
State media downplayed the severity of the outbreak.
Past the peak
An article in Health Times, a publication managed by People's Daily, the ruling Communist Party's official newspaper, quoted several officials as saying infections have been declining in the capital Beijing and several Chinese provinces.
Officials in the southern technology powerhouse Shenzhen announced on Tuesday that the city had also passed its peak.
Kan Quan, director of the Office of the Henan Provincial Epidemic Prevention and Control, said nearly 90 per cent of people in the central province of 100 million people had been infected as of 6 January.
In the eastern province of Jiangsu, the peak was reached on 22 December, while in neighbouring Zheijiang province "the first wave of infections has passed smoothly," officials said.
Pfizer criticism
The border rules were not the only COVID conflict brewing in China.
State media lashed out at Pfizer over the price for its COVID treatment Paxlovid.
"It is not a secret that US capital forces have already accumulated quite a fortune from the world via selling vaccines and drugs, and the US government has been coordinating all along," nationalist tabloid Global Times said in an editorial.
Pfizer's Chief Executive Albert Bourla said on Monday the company was in discussions with Chinese authorities about a price for Paxlovid, but not over licensing a generic version in China.
China's abrupt change of course in COVID policies has caught many hospitals ill-equipped, while smaller cities were left scrambling to secure basic anti-fever drugs.
Yu Weishi, chairman of Youcare Pharmaceutical Group, told Reuters his firm boosted output of its anti-fever drugs five-fold to one million boxes a day in the past month.
